CTOs on the Move

OptionCare

www.optioncare.com

 
Option Care is a leading provider of home and alternate treatment site infusion services. With a staff of more than 1,700 clinical experts – including specially trained infusion nurses, infusion pharmacists and registered dietitians – Option Care treats patients with a wide range of acute and chronic conditions. Comprehensive therapy management programs are offered for patients with nutrition disorders, bleeding disorders and heart failure, as well as those needing immunoglobulin (IG) therapy and anti-infective therapy. Option Care is able to provide services to 92% of the nation`s population through more than 90 infusion pharmacies and 100 alternate treatment ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.optioncare.com
  • 485 E Half Day Rd Ste 300
    Buffalo Grove, IL USA 60089
  • Phone: 800.879.6137

Executives

Name Title Contact Details

Similar Companies

Cylene Pharmaceuticals

Cylene Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sirnaomics

Sirnaomics, Inc. is a biopharmaceutical company discovering and developing novel targeted therapeutics for critical human diseases by using RNA interference (RNAi) technology.

PCI Pharma Services

PCI is a leading provider of integrated pharmaceutical development services to the global healthcare market.

Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.

Inizio

Inizio is a strategic partner for health and life sciences with a full suite of medical, marketing, advisory and engagement services throughout the drug lifecycle.